Market Cap
$221.9M
KROS
Keros Therapeutics, Inc.
$11.20 ▼ -0.53%
Prev close $11.26Market cap$221.9M
ConsensusBuy
12-mo target$19.83 (+77.1%)
▲ Bullish
Analyst conviction 7/10
Insider Selling Cluster (5 insiders)19 New Institutional Positions21 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on KROS right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Buy (69%)
Inst. Holders
50 funds
Inst. Value
$150.9M
Inst. Activity
19 buys / 21 sells
Insider Activity
$75.8K buy / $522.9K sell
Insider Net $
-$447.2K
SEC Reports
15
Press Releases
2
Price chart 30d -0.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 28, 2026 fda
Sep 9, 2026 SEC Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
Initial data expected in the first half of 2027 Initial data expected in the first half of 2027
Keros Therapeutics announced a $5 million share repurchase authorization following a $20 million development milestone p
8-K — Impact 4/10
Keros Therapeutics insiders executed a mixed cluster: one director bought $10K worth of shares, while three C-suite offi
CLUSTER — Impact 4/10
Aug 18, 2026 Insider
Newton Charles W. sold 551 shares
Director @ $10.30 ($5.7K)
Aug 18, 2026 Insider
Tanini Annita sold 1,224 shares
Corp. Controller & VP, Finance @ $10.29 ($12.6K)
Aug 18, 2026 Insider
Aug 3, 2026 SEC Cho Esther sold 4,485 shares
Chief Legal Officer @ $10.29 ($46.2K)
Keros Therapeutics reported Q2 2026 results with a net loss of $28.7M ($1.45/share), slightly narrower than the $30.7M l
8-K — Impact 4/10
Jun 30, 2026 Inst.
MACKENZIE FINANCIAL CORP — DOUBLED
628,438 shares ($6.7M)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
69% rate it Buy or better · 13 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 4, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| Aug 4, 2026 | Leerink Partners | MAINTAIN | Outperform | 49% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 6 | 4 | 0 | 0 | 69% | |
| Aug 1, 2026 | 3 | 6 | 5 | 0 | 0 | 64% | |
| Jul 1, 2026 | 3 | 6 | 5 | 0 | 0 | 64% | |
| Jun 1, 2026 | 3 | 6 | 5 | 0 | 0 | 64% | |
| May 1, 2026 | 4 | 6 | 5 | 0 | 0 | 67% | |
| Apr 1, 2026 | 4 | 6 | 5 | 0 | 0 | 67% | |
| Mar 1, 2026 | 4 | 6 | 5 | 0 | 0 | 67% | |
| Feb 1, 2026 | 5 | 6 | 5 | 0 | 0 | 69% |
Price targets
Where 6 covering analysts think KROS trades over the next 12 months.
$19.83 +77.1% upside Strong Buy
Current$11.20 Low$16.00 Median$19.00 High$25.00 6 analysts
$16.00$25.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
15 SEC filing reports analyzed · 1 bullish, 2 bearish, 2 mixed, 10 neutral · avg impact 4.0/10.Plus 2 press releases.
NEUTRAL8-K4/10
Keros Therapeutics announced a $5 million share repurchase authorization following a $20 million dev
Sep 9, 2026
NEUTRALCLUSTER4/10
Keros Therapeutics insiders executed a mixed cluster: one director bought $10K worth of shares, whil
Aug 21, 2026
NEUTRAL8-K4/10
Keros Therapeutics reported Q2 2026 results with a net loss of $28.7M ($1.45/share), slightly narrow
Aug 3, 2026
NEUTRALPRESS-RELEASE3/10
Keros Therapeutics reported Q2 2026 net loss of $28.7M (EPS -$1.45), missing consensus EPS of -$1.24
Aug 3, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 28, 2026
fda
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
Initial data expected in the first half of 2027 Initial data expected in the first half of 2027
Sep 8, 2026
contract
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
LEXINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceu
Aug 12, 2026
earnings_calendar
KROS Q2 2026 Earnings Before Market Open — 2026-08-12
Aug 4, 2026
earnings_calendar
KROS Q2 2026 Earnings Before Market Open — 2026-08-04
Aug 3, 2026
earnings
Keros Therapeutics Reports Second Quarter 2026 Financial Results
LEXINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceut
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.86 | $-1.53–$-0.56 | -377.8% | +33.7% | 3↑ 1↓ | $0.0B | 4 |
| Next Q | $-1.78 | $-1.97–$-1.49 | -107.0% | -23.6% | 0↑ 5↓ | $0.0B | 5 |
| Current FY | $-5.22 | $-5.90–$-4.62 | -327.0% | -0.7% | 3↑ 2↓ | $0.0B | 5 |
| Next FY | $-6.62 | $-8.93–$-3.84 | -26.7% | -18.3% | 0↑ 6↓ | $0.0B | 5 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.860 | — |
| 7d ago | $-0.788 | -0.072 |
| 30d ago | $-1.298 | +0.438 |
| 60d ago | $-1.298 | +0.438 |
| 90d ago | $-1.345 | +0.485 |
Institutional ownership
Which big funds own KROS (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $150.9M total value (14,097,381 shares) as of 2026-Q2. Top holders: BlackRock,, AQR, VANGUARD. Net selling activity: 21 institutions trimmed/exited vs 19 added.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 2,794,217 | $29.9M | 19.8% | — |
| AQR CAPITAL MANAGEMENT LLC | 967,859 | $10.4M | 6.9% | DOUBLED +125.2% |
| VANGUARD CAPITAL MANAGEMENT LLC | 833,596 | $8.9M | 5.9% | — |
| FEDERATED HERMES, INC. | 700,427 | $7.5M | 5.0% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 652,635 | $7.0M | 4.6% | — |
| MACKENZIE FINANCIAL CORP | 628,438 | $6.7M | 4.5% | DOUBLED +312.2% |
| Qube Research & Technologies Ltd | 608,837 | $6.5M | 4.3% | — |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 605,445 | $6.5M | 4.3% | — |
| STATE STREET CORP | 541,193 | $5.8M | 3.8% | TRIM -47.8% |
| GEODE CAPITAL MANAGEMENT, LLC | 510,841 | $5.5M | 3.6% | TRIM -25.0% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MACKENZIE FINANCIAL CORP | DOUBLED | 152,450 | 628,438 | +312.2% | $6.7M |
| GEODE CAPITAL MANAGEMENT, LLC | TRIM | 681,460 | 510,841 | -25.0% | $5.5M |
| DIMENSIONAL FUND ADVISORS LP | ADD | 321,360 | 460,541 | +43.3% | $4.9M |
| D. E. Shaw & Co., Inc. | TRIM | 509,608 | 267,460 | -47.5% | $2.9M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | TRIM | 590,249 | 233,175 | -60.5% | $2.5M |
| MILLENNIUM MANAGEMENT LLC | ADD | 106,858 | 184,822 | +73.0% | $2.0M |
| Man Group plc | TRIM | 238,618 | 155,541 | -34.8% | $1.7M |
| NORTHERN TRUST CORP | TRIM | 254,187 | 153,843 | -39.5% | $1.6M |
| Connor, Clark & Lunn Investment Management Ltd. | TRIM | 257,884 | 127,885 | -50.4% | $1.4M |
| JANE STREET GROUP, LLC | DOUBLED | 44,457 | 115,267 | +159.3% | $1.2M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 38 transactions. Net -$447.2K — $75.8K bought, $522.9K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | Newton Charles W. | Director | SELL | 551 | $10.30 | $5.7K |
| Aug 18, 2026 | Tanini Annita | Corp. Controller & VP, Finance | SELL | 1,224 | $10.29 | $12.6K |
| Aug 18, 2026 | Cho Esther | Chief Legal Officer | SELL | 4,485 | $10.29 | $46.2K |
| Aug 18, 2026 | Lerner Lorena Raquel | Chief Scientific Officer | SELL | 3,568 | $10.29 | $36.7K |
| Aug 17, 2026 | BIENAIME JEAN JACQUES | Director | BUY | 1,000 | $10.27 | $10.3K |
| Jul 15, 2026 | BIENAIME JEAN JACQUES | Director | BUY | 1,000 | $10.61 | $10.6K |
| Jul 1, 2026 | Prener Anne | Director | AWARD | 14,870 | — | — |
| Jul 1, 2026 | Prener Anne | Director | AWARD | 13,786 | — | — |
| Jun 15, 2026 | BIENAIME JEAN JACQUES | Director | BUY | 1,000 | $10.19 | $10.2K |
| Jun 11, 2026 | Newton Charles W. | Director | SELL | 550 | $10.04 | $5.5K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for KROS.
Shares short
1,342,620
Settlement Sep 15, 2026
Change vs prior
+15.2%
Semi-monthly cycle
Days to cover
9.1
At avg daily volume
Of shares outstanding
≈6.8%
Estimate — not % of float
All KROS filing & press-release reports (17)
- 8-K reportSep 9, 2026
- CLUSTER reportAug 21, 2026
- 8-K reportAug 3, 2026
- PRESS-RELEASE reportAug 3, 2026
- 8-K reportJul 30, 2026
- 8-K reportJul 22, 2026
- CLUSTER reportJun 17, 2026
- CLUSTER reportJun 8, 2026
- 8-K reportMay 14, 2026
- PRESS-RELEASE reportMay 14, 2026
- DEFA14A reportApr 22, 2026
- 144 reportApr 1, 2026
- PRESS-RELEASE reportMar 9, 2026
- 8-K reportMar 4, 2026
- 8-K reportMar 4, 2026
- PRESS-RELEASE reportMar 4, 2026
- INST-CLUSTER reportFeb 28, 2026